The one-year cost for medullary thyroid cancer patients treated with targeted drugs is uncertain, due to the different target drugs, local medical insurance reimbursement ratio, and side effects of patients after using the drugs, so the cost varies, and the rough estimation is between 50,000~100,000 yuan. Medullary thyroid cancer is relatively high in malignancy, early stage patients can be operated, but late stage patients lose the chance of operation and are not sensitive to radiotherapy, so some targeted drugs are often chosen for treatment, and at present, clinically available targeted drugs include anilotinib, cabozantinib, sorafenib, sofantinib, etc. Patients with different conditions and physique are different, so the cost varies. Patients have different conditions and physical conditions, so there will be differences in the selection of targeted drugs, and patients with different side effects after using the drug, so patients need to bear the cost is not the same. Drugs should be used under the guidance of a doctor, do not blindly use and stop medication, so as not to delay the condition.